Prescient Therapeutics Management
Management criteria checks 3/4
Prescient Therapeutics' CEO is Steven Yatomi-Clarke, appointed in Feb 2016, has a tenure of 8.25 years. total yearly compensation is A$663.24K, comprised of 60.3% salary and 39.7% bonuses, including company stock and options. directly owns 1.39% of the company’s shares, worth A$470.19K. The average tenure of the management team and the board of directors is 8.3 years and 9 years respectively.
Key information
Steven Yatomi-Clarke
Chief executive officer
AU$663.2k
Total compensation
| CEO salary percentage | 60.3% |
| CEO tenure | 8.3yrs |
| CEO ownership | 1.4% |
| Management average tenure | 8.3yrs |
| Board average tenure | 9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -AU$8m |
| Sep 30 2023 | n/a | n/a | -AU$7m |
| Jun 30 2023 | AU$663k | AU$400k | -AU$7m |
| Mar 31 2023 | n/a | n/a | -AU$6m |
| Dec 31 2022 | n/a | n/a | -AU$5m |
| Sep 30 2022 | n/a | n/a | -AU$5m |
| Jun 30 2022 | AU$771k | AU$392k | -AU$5m |
| Mar 31 2022 | n/a | n/a | -AU$5m |
| Dec 31 2021 | n/a | n/a | -AU$5m |
| Sep 30 2021 | n/a | n/a | -AU$5m |
| Jun 30 2021 | AU$800k | AU$360k | -AU$4m |
| Mar 31 2021 | n/a | n/a | -AU$4m |
| Dec 31 2020 | n/a | n/a | -AU$3m |
| Sep 30 2020 | n/a | n/a | -AU$3m |
| Jun 30 2020 | AU$639k | AU$392k | -AU$3m |
| Mar 31 2020 | n/a | n/a | -AU$4m |
| Dec 31 2019 | n/a | n/a | -AU$4m |
| Sep 30 2019 | n/a | n/a | -AU$4m |
| Jun 30 2019 | AU$586k | AU$367k | -AU$4m |
| Mar 31 2019 | n/a | n/a | -AU$3m |
| Dec 31 2018 | n/a | n/a | -AU$3m |
| Sep 30 2018 | n/a | n/a | -AU$3m |
| Jun 30 2018 | AU$479k | AU$330k | -AU$3m |
| Mar 31 2018 | n/a | n/a | -AU$3m |
| Dec 31 2017 | n/a | n/a | -AU$3m |
| Sep 30 2017 | n/a | n/a | -AU$3m |
| Jun 30 2017 | AU$502k | AU$316k | -AU$3m |
Compensation vs Market: Steven's total compensation ($USD438.39K) is above average for companies of similar size in the Australian market ($USD296.51K).
Compensation vs Earnings: Steven's compensation has been consistent with company performance over the past year.
CEO
Steven Yatomi-Clarke
8.3yrs
Tenure
AU$663,236
Compensation
Mr. Steven Lee Yatomi-Clarke has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Yatomi-Clarke has been Director of Prescient Therapeutics...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 8.3yrs | AU$663.24k | 1.39% A$ 470.2k | |
| CFO & Company Secretary | 9.3yrs | AU$158.40k | no data | |
| Director of Clinical Affairs & Operations | 3.3yrs | no data | no data | |
| Chief Medical Officer | 9.1yrs | AU$157.36k | no data | |
| Senior Vice President of Scientific Affairs | 2.3yrs | no data | no data |
8.3yrs
Average Tenure
Experienced Management: PTX's management team is seasoned and experienced (8.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 9.5yrs | AU$663.24k | 1.39% A$ 470.2k | |
| Independent Non-Executive Chairman | 9.9yrs | AU$106.05k | 0.027% A$ 9.2k | |
| Independent Non-Executive Director | 9.5yrs | AU$65.26k | 0.049% A$ 16.6k | |
| Chairman of Clinical Advisory Board | 12.9yrs | no data | no data | |
| Member of Clinical Advisory Board | 12.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Non-Executive Director | 3.9yrs | AU$65.26k | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data |
9.0yrs
Average Tenure
Experienced Board: PTX's board of directors are considered experienced (9 years average tenure).